Safety and efficacy of activated transfected killer cells for neutropenic fungal infections

Journal of Infectious Diseases

Volumn 201, Issue 11, 2010, Pages 1708-1717

  Lin, Lin ^a   Ibrahim, Ashraf S ^a,b   Baquir, Beverlie ^a   Fu, Yue ^a,b   Applebaum, David ^a   Schwartz, Julie ^c   Wang, Amy ^a   Avanesian, Valentina ^a   Spellberg, Brad ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Charles River Laboratories Pathology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; GANCICLOVIR; RETINOIC ACID; THYMIDINE KINASE;

ACTIVATED TRANSFECTED KILLER CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; AUTOPSY; BIOLUMINESCENCE; BLOOD SAMPLING; CELL THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; METABOLOMICS; MOUSE; MYCOSIS; NEUTROPENIA; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SURVIVAL; TISSUE INJURY;

ADOPTIVE TRANSFER; ANIMALS; ASPERGILLOSIS; CANDIDIASIS; FEMALE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTROPENIA; SURVIVAL ANALYSIS; THYMIDINE KINASE; TRANSFECTION;

EID: 77951912884     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652496     Document Type: Article

References (37)

1. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-409 (Pubitemid 46147624)
2. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007;45:321-346 (Pubitemid 46839802)
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360 (Pubitemid 351265310)
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917 (Pubitemid 34229758)
6. Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008;21:409-414
7. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-989
8. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105:478-483
9. Nucci M, Pulcheri W, Spector N, et al. Fungal infections in neutropenic patients: an 8-year prospective study. Rev Inst Med Trop Sao Paulo 1995; 37:397-406. (Pubitemid 26027660)
10. Lehrnbecher T, Groll AH, Chanock SJ. Treatment of fungal infections in neutropenic children. Curr Opin Pediatr 1999; 11:47-55. (Pubitemid 29090071)
11. Hübel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 2001;183:321-328 (Pubitemid 32066035)
12. Alavi JB, Root RK, Djerassi L, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977;296:706-711
13. Herzig RH, Herzig GP, Graw RG Jr, Bull MI, Ray KK. Successful granulocyte transfusion therapy for gram-negative septicemia: a prospectively randomized controlled study. N Engl J Med 1977; 296:701-705
14. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. XI. Blood granulocyte kinetics in polycythemia vera, infection, and myelofibrosis. J Clin Invest 1965;44:778-788
15. Marsh JC, Boggs DR, Cartwright GE, Wintrobe MM. Neutrophil kinetics in acute infection. J Clin Invest 1967;46:1943-1953
16. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest 1976;58:705-715
17. Huestis DW, Glasser L. The neutrophil in transfusion medicine. Transfusion 1994; 34:630-646
18. Glasser L. Effect of storage on normal neutrophils collected by discontinuous-flow centrifugation leukapheresis. Blood 1977; 50:1145-1150 (Pubitemid 8245217)
19. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859-2865
20. Spellberg BJ, Collins M, Avanesian V, et al. Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol 2006;81:632-641 (Pubitemid 46393541)
21. Spellberg BJ, Collins M, French SW, Edwards JE Jr, Fu Y, Ibrahim AS. A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol 2005; 78:338-414 (Pubitemid 41061306)
22. Spellberg BJ, Johnston D, Phan QT, et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003;71:5756-5764 (Pubitemid 37205629)
23. Van t Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989;33:147-151
24. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004;48:1908-1911
25. Rieg G, Spellberg B, Schwartz J, et al. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:2895-2896
26. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009;48:399-418.
27. Winston DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006; 12: 635-710
28. Ohta T, Masutomi N, Tsutsui N, et al. Metabolomics analysis of plasma and urine in rats treated with fenofibrate and phenobarbital. In: Program and abstracts of the 47th annual meeting of the Society of Toxicology (Seattle). Reston, VA: Society of Toxicology, 2008.
29. Rosenstock M, Boudonck K. Metabolomic analysis of urine and kidney tissue in rats treated with valproate. In: Advances in Metabolic Pro- filing, European Biomarkers Summit and Proteomics Europe (Lisbon, Portugal). 2008.
30. Mohney RP, Zhou H, Liu L, Mitchell M, Guha C. Metabolomic profiles of liver and plasma following whole-liver irradiation in mice. In: Program and abstracts of the 47th annual meeting of the Society of Toxicology (Seattle). Reston, VA: Society of Toxicology, 2008.
31. van Bekkum DW. Use and abuse of hemopoietic cell grafts in immune deficiency diseases. Transplant Rev 1972; 9:3-53.
32. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK92. J Hematother Stem Cell Res 2001; 10:535-614
33. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-7028 (Pubitemid 23222381)
34. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. Anticancer Res 1999; 19:2163-2165 (Pubitemid 29392516)
35. Tong X, Engehausen DG, Freund CT, et al. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 1999; 18:93-97 (Pubitemid 29140428)
36. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-1552
37. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase 1 clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092 (Pubitemid 28236516)